Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 1
- Registration Number
- NCT05461235
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 96
- Registration Number
- NCT05461794
- Locations
- 🇨🇳
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu, Sichuan, China
🇨🇳Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2022-07-08
- Target Recruit Count
- 50
- Registration Number
- NCT05448885
- Locations
- 🇨🇳
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijing, Beijing, China
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 39
- Registration Number
- NCT05435313
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Dose Escalation/Expansion Study of PT199 (an Anti-CD73 mAb) Administered Alone and in Combination With a PD-1 Inhibitor (the MORNINGSTAR Study)
- Conditions
- Interventions
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05431270
- Locations
- 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸Tranquility Research, Webster, Texas, United States
🇺🇸Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma, United States
Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05406466
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05401279
- Locations
- 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05394415
- Locations
- 🇨🇳
Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 35
- Registration Number
- NCT05366829
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-05-17
- Target Recruit Count
- 20
- Registration Number
- NCT05350917
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.